178 related articles for article (PubMed ID: 10354947)
1. [Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders].
Raue F
Internist (Berl); 1999 Apr; 40(4):448-55. PubMed ID: 10354947
[No Abstract] [Full Text] [Related]
2. The therapeutic use of bisphosphonates.
Compston JE
BMJ; 1994 Sep; 309(6956):711-5. PubMed ID: 7950525
[No Abstract] [Full Text] [Related]
3. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
4. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
5. [Development of bisphosphonates].
Nakatsuka K
Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin therapy for bone disease and hypercalcemia.
Avioli LV
Arch Intern Med; 1982 Nov; 142(12):2076-9. PubMed ID: 7138154
[No Abstract] [Full Text] [Related]
7. Pamidronate.
Med Lett Drugs Ther; 1992 Jan; 34(861):1-2. PubMed ID: 1728727
[No Abstract] [Full Text] [Related]
8. Bisphosphonates in the treatment of metabolic bone diseases.
Rodan GA; Balena R
Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
[TBL] [Abstract][Full Text] [Related]
9. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: an overview with special reference to alendronate.
Vasikaran SD
Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in the treatment of disorders of mineral metabolism.
Singer FR; Minoofar PN
Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in the treatment of malignant bone disease.
Berenson JR; Lipton A
Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
[TBL] [Abstract][Full Text] [Related]
13. [Bisphosphonates in pharmacotherapy of bone diseases].
Iur'ieva EA; Matkovskaia TA; Elagina IA; Stoliarov IuIu
Eksp Klin Farmakol; 2000; 63(3):74-9. PubMed ID: 10934603
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates use in children.
Sebestyen JF; Srivastava T; Alon US
Clin Pediatr (Phila); 2012 Nov; 51(11):1011-24. PubMed ID: 22935217
[TBL] [Abstract][Full Text] [Related]
16. [Malignancy-associated hypercalcemia].
Oura S
Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
[TBL] [Abstract][Full Text] [Related]
17. [Biphosphonate therapy in the management of skeletal metastases].
Grauer A; Ziegler R
Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
[TBL] [Abstract][Full Text] [Related]
18. Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.
Patel S; Lyons AR; Hosking DJ
Drugs; 1993 Oct; 46(4):594-617. PubMed ID: 7506648
[TBL] [Abstract][Full Text] [Related]
19. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
20. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
